Annual ROE
-1130.31%
-588.30%-108.54%
December 1, 2023
Summary
- As of February 25, 2025, RNAZ annual return on equity is -1130.31%, with the most recent change of -588.30% (-108.54%) on December 1, 2023.
- During the last 3 years, RNAZ annual ROE has fallen by -1199.08% (-1743.61%).
- RNAZ annual ROE is now -1743.61% below its all-time high of 68.77%, reached on December 31, 2020.
Performance
RNAZ ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
-649.01%
-51.54%-8.63%
September 1, 2024
Summary
- As of February 25, 2025, RNAZ quarterly return on equity is -649.01%, with the most recent change of -51.54% (-8.63%) on September 1, 2024.
- Over the past year, RNAZ quarterly ROE has stayed the same.
- RNAZ quarterly ROE is now -637.97% below its all-time high of 120.64%, reached on March 31, 2021.
Performance
RNAZ Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
RNAZ ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -108.5% | 0.0% |
| 3 y3 years | -1743.6% | 0.0% |
| 5 y5 years | -2166.0% | 0.0% |
RNAZ ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -3270.0% | at low | -1445.6% | +30.6% |
| 5 y | 5-year | -1743.6% | at low | -638.0% | +30.6% |
| alltime | all time | -1743.6% | at low | -638.0% | +30.6% |
TransCode Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | -649.01%(+8.6%) |
| Jun 2024 | - | -597.47%(+11.7%) |
| Mar 2024 | - | -534.78%(-42.8%) |
| Dec 2023 | -1130.31%(+108.5%) | -934.74%(+13.7%) |
| Sep 2023 | - | -821.82%(+47.5%) |
| Jun 2023 | - | -557.17%(+74.4%) |
| Mar 2023 | - | -319.51%(+86.1%) |
| Dec 2022 | -542.01% | -171.73%(+63.7%) |
| Sep 2022 | - | -104.90%(+44.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | -72.73%(+73.2%) |
| Mar 2022 | - | -41.99%(-52.9%) |
| Dec 2021 | -33.54%(-148.8%) | -89.23%(-68.4%) |
| Sep 2021 | - | -282.31%(-494.1%) |
| Jun 2021 | - | 71.64%(-40.6%) |
| Mar 2021 | - | 120.64%(+75.4%) |
| Dec 2020 | 68.77%(+25.7%) | - |
| Dec 2020 | - | 68.77% |
| Dec 2019 | 54.71% | - |
FAQ
- What is TransCode Therapeutics annual return on equity?
- What is the all time high annual ROE for TransCode Therapeutics?
- What is TransCode Therapeutics annual ROE year-on-year change?
- What is TransCode Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly ROE year-on-year change?
What is TransCode Therapeutics annual return on equity?
The current annual ROE of RNAZ is -1130.31%
What is the all time high annual ROE for TransCode Therapeutics?
TransCode Therapeutics all-time high annual return on equity is 68.77%
What is TransCode Therapeutics annual ROE year-on-year change?
Over the past year, RNAZ annual return on equity has changed by -588.30% (-108.54%)
What is TransCode Therapeutics quarterly return on equity?
The current quarterly ROE of RNAZ is -649.01%
What is the all time high quarterly ROE for TransCode Therapeutics?
TransCode Therapeutics all-time high quarterly return on equity is 120.64%
What is TransCode Therapeutics quarterly ROE year-on-year change?
Over the past year, RNAZ quarterly return on equity has changed by 0.00% (0.00%)